Carlos Fabiano Capato

Mrs. Carlos Fabiano Capato


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MFMarcilio Fumagalli
Marcilio Fumagalli
LCLuiza Antunes Castro-Jorge
Luiza Antunes Castro-Jorge
Thais Fernanda de Campos Fraga-SilvaThais Fernanda de Campos Fraga-Silva
Thais Fernanda de Campos Fraga-Silva
PAPatrick Orestes de Azevedo
Patrick Orestes de Azevedo
CCCarlos Fabiano Capato
Carlos Fabiano Capato
LFLuiz Tadeu Figueiredo
Luiz Tadeu Figueiredo
The persistent circulation of SARS-CoV-2 represents an ongoing global threat due to the emergence of new viral variants that can sometimes evade the immune system of previously exposed or vaccinated individuals. We conducted a follow-up study of adult individuals that had received an inactivated SARS-CoV-2 vaccine, evaluating antibody production and neutralizing activity over a period of 6 months. In addition, we performed mice immunization with inactivated SARS-CoV-2, and evaluated the immune response and pathological outcomes against Gamma and Zeta variant infection. Vaccinated individuals produced high levels of antibodies with robust neutralizing activity, which was significantly reduced against Gamma and Zeta variants. Production of IgG anti-S antibodies and neutralizing activity robustly reduced after 6 months of vaccination. Immunized mice demonstrated cellular response against Gamma and Zeta variants, and after viral infection, reduced viral loads, IL-6 expression, and histopathological outcome in the lungs. TNF levels were unchanged in immunized or not immunized mice after infection with the Gamma variant. Furthermore, serum neutralization activity rapidly increases after infection with the Gamma and Zeta variants. Our data suggest that immunization with inactivated WT SARS-CoV-2 induces a promptly responsive cross-reactive immunity response against the Gamma and Zeta variants, reducing COVID-19 pathological outcomes.